Alnylam Pharmaceuticals Slumps to 467th in Trading Volume Despite FDA Approval for AMVUTTRA

On June 25, 2025, Alnylam Pharmaceuticals Inc. (ALNY) experienced a significant decline, with its trading volume reaching $204 million, a 36.59% decrease from the previous day. This placed ALNY at the 467th position in terms of trading volume for the day. The stock price of ALNY also decreased by 0.94%.

Alnylam Pharmaceuticals Inc. recently received FDA approval for AMVUTTRA (vutrisiran), marking a significant milestone as the first RNAi therapeutic to reduce cardiovascular death and hospitalizations. This approval is expected to have a positive impact on the company's market position and financial performance.

Additionally, the European Commission (EC) has granted approval for Alnylam's Amvuttra to treat the rare heart disease ATTR-CM. This approval further solidifies Alnylam's leadership in the development of innovative therapies for rare diseases, potentially driving future growth and investor confidence.